Eastman Kodak

WXXI Photo

A government watchdog agency has found no wrongdoing in the process that led up to the announcement of a proposed loan to Eastman Kodak in the summer. The loan did not come to fruition after concerns about how the loan details came together.

WXXI Photo

A top Kodak official said the company still plans to move ahead with its pharmaceutical business, even if it doesn’t get a government loan.

Kodak CEO Jim Continenza told investors on the company's quarterly earnings conference call Tuesday that the company still wants to push ahead with its plans for making ingredients used in pharmaceuticals, even with the questions raised in the summer that caused the federal government to put a hold on a $765 million loan to the company. Continenza made similar comments at a conference last month held by the Wall Street Journal.

WXXI Photo

Eastman Kodak CEO Jim Continenza says the company will continue to move forward in making drug ingredients for generic pharmaceuticals, even if it doesn't get help from the federal government. Continenza made the comments at a tech conference sponsored by the Wall Street Journal Monday.

Eastman Kodak is releasing findings from an internal review of its financial dealings in connection with the allegations swirling around the possibility it might get a $765 million federal loan to make ingredients used in pharmaceuticals.

The company commissioned an independent legal review of issues including how stock options were granted to executives, and the timing of the announcement of the potential loan.

WXXI Photo

The inspector general of the federal agency that helped put together a planned $765 million dollar loan for Eastman Kodak is reviewing that deal.

WXXI Photo

A top White House official is blasting Kodak for how the company has handled a potential government loan to make pharmaceutical ingredients.

White House Trade Advisor Peter Navarro made the comments on CNBC on Monday when asked about that $765 million federal loan that Navarro and other officials talked about last month for the Rochester company.

Kodak’s top official is talking about the status of the company’s potential federal loan, a deal which has created a lot of controversy in recent days.

Executive Chairman Jim Continenza made a few brief comments about the potential loan during the company’s second-quarter earnings conference call on Tuesday.

The $765 million loan, announced two weeks ago, would help Kodak gear up to make ingredients used in generic drugs.

WXXI Photo

Eastman Kodak shares tumbled on Monday, after a federal agency said last Friday that it would hold off on moving ahead with a $765 million loan to the company to help it make ingredients used in generic drugs. The stock fell nearly 28%, to $10.73 a share on Monday.

Emily Hunt for WXXI News

The federal agency that announced on July 28 that it was signing a letter of intent to provide a $765 million loan to Eastman Kodak, so that the company could establish a pharmaceutical division to make ingredients for generic drugs is now apparently putting a hold on moving ahead with that financing.

WXXI Photo

Eastman Kodak has appointed a special committee of independent members of its Board of Directors to look into recent activity surrounding a $765 million federal loan.

That loan is intended to help Kodak develop a pharmaceutical division to produce ingredients used for generic drugs, to make the U.S. less dependent on foreign sources for those medications.